OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 531 - 540 of 797 studies

Investigating human biology of resident immunity in tissue via neoantigen challenge

Metabolic and Endocrine

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01Positive Participants With Type 1 Diabetes (IMC-S118AI-1007)

Musculoskeletal

A Phase 3, Multi centre, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Musculoskeletal

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) (ENTR-601-DMD-202 (ELEVATE-LTE))

Neurological

NIO752 A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy of NIO752 in participants with Progressive Supranuclear palsy followed by an Open Label Extension (CNIO752A12301 (PRESERVE))

Comparative evaluation of sustained meChanical AsPiration Thrombectomy and no thrombus modification for pre-stent thrombus bUrden Reduction in patients with Acute Myocardial Infarction Study: the CAPTURE AMI Study

Cancer and neoplasms

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Fluoropyrimidine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (D9803C00001 (CLARITY-Gastric 02))

CAPTIVATE - Diet-driven gut microbiome and outcome in patients with early-stage triple-negative breast cancer undergoing neoadjuvant chemotherapy and immunotherapy

Respiratory

A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])

Musculoskeletal

IDUN: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI) (IDUN)